Companies: 48,686 Total Market Cap: 130293247649035.64

Insulet

NASDAQ: PODD
Healthcare Medical Devices
Rank #916
Market Cap 22.55 B
Volume 28,252
Price 320.39
Change (%) 1.17%
Country or region United States United States

Insulet's latest marketcap:

22.55 B

As of May 13, 2025, Insulet's market capitalization has reached $22.55 B. According to our data, Insulet is the 916th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 22.55 B
Revenue (ttm) 2.20 B
Net Income (ttm) 402.20 M
Shares Out 70.37 M
EPS (ttm) 5.55
Forward PE 71.63
Ex-Dividend Date n/a
Earnings Date May 8, 2025
Market Cap Chart
Data Updated: May 13, 2025

Insulet's yearly market capitalization.

Insulet has seen its market value grow from $620.60 M to $22.55 B since 2007, representing a total increase of 3,533.16% and an annual compound growth rate (CAGR) of 22.98%.
Date Market Cap Change (%)
May 13, 2025 $22.55 B 19.39%
December 31, 2024 $18.31 B 20.87%
December 29, 2023 $15.15 B -25.89%
December 30, 2022 $20.45 B 11.42%
December 31, 2021 $18.35 B 8.88%
December 31, 2020 $16.85 B 59.23%
December 31, 2019 $10.58 B 125.86%
December 31, 2018 $4.69 B 16.71%
December 29, 2017 $4.02 B 85.55%
December 30, 2016 $2.16 B 0.52%
December 31, 2015 $2.15 B -16.67%
December 31, 2014 $2.58 B 27.66%
December 31, 2013 $2.02 B 97.96%
December 31, 2012 $1.02 B 14.53%
December 30, 2011 $892.40 M 37.59%
December 31, 2010 $648.60 M 47.51%
December 31, 2009 $439.70 M 105.18%
December 31, 2008 $214.30 M -65.47%
December 31, 2007 $620.60 M

Company Profile

Insulet Corporation Overview

Insulet Corporation is a leading developer and manufacturer of innovative insulin delivery systems designed for individuals with insulin-dependent diabetes. The company operates both in the United States and internationally, providing cutting-edge solutions to improve diabetes management.

Key Products

  • Omnipod 5 Automated Insulin Delivery System: Features a proprietary AID algorithm embedded in the pod, integrating with third-party continuous glucose monitors via Bluetooth for seamless glucose monitoring.
  • Omnipod DASH Insulin Management System: Includes a Bluetooth-enabled pod controlled by a smartphone-like personal diabetes manager with a user-friendly color touch screen interface.
  • Pods for Amgen's Neulasta Onpro Kit: Utilized in a delivery system aimed at reducing infection risk post-chemotherapy.

Distribution Channels

Insulet Corporation markets its products directly to end-users through the pharmacy channel and collaborates with independent distributors to ensure widespread accessibility.

Company Background

Founded in 2000, Insulet Corporation is headquartered in Acton, Massachusetts, and continues to drive innovation in diabetes care technology.

Frequently Asked Questions

As of May 13, 2025, Insulet (including the parent company, if applicable) has an estimated market capitalization of $22.55 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Insulet global market capitalization ranking is approximately 916 as of May 13, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region United States
Founded 2000
IPO Date May 15, 2007
Employees 3,900
CEO James Hollingshead
Sector Healthcare
Industry Medical Devices
Address 100 Nagog Park
Acton, Massachusetts 01720
United States
People Also Watch
ABT
130.91 1.17%
BSX
103.04 1.17%
SYK
388.35 1.17%
MDT
85.10 1.17%